1800 Participants Needed

Therapeutic Hypothermia for Cardiac Arrest

(ICECAP Trial)

Recruiting at 61 trial locations
WM
MS
NB
Overseen ByNia Bozeman
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Michigan
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 3 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

A multicenter, randomized, adaptive allocation clinical trial to determine if increasing durations of induced hypothermia are associated with an increasing rate of good neurological outcomes and to identify the optimal duration of induced hypothermia for neuroprotection in comatose survivors of cardiac arrest.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Therapeutic Hypothermia for Cardiac Arrest?

Therapeutic hypothermia has been shown to improve survival and neurological outcomes in patients who survive cardiac arrest. Studies indicate that faster cooling leads to better outcomes, and implementing a targeted temperature protocol can help achieve this. Additionally, therapeutic hypothermia is part of current guidelines for post-resuscitation care, highlighting its importance in improving patient recovery.12345

Is therapeutic hypothermia generally safe for humans?

Therapeutic hypothermia can have side effects, including issues with the heart, fluid balance, and infections, and it requires careful monitoring and management. These side effects are seen in various conditions, including cardiac arrest and severe brain injury, and more research is needed to fully understand and manage these risks.678910

How is the treatment Therapeutic Hypothermia unique for cardiac arrest?

Therapeutic Hypothermia is unique because it involves cooling the body to a target temperature of 32-34°C to improve survival and brain function after cardiac arrest, unlike other treatments that do not focus on temperature management. It is one of the few advancements that has shown to improve outcomes in cardiac arrest patients, especially when started early after resuscitation.12111213

Research Team

WM

William Meurer

Principal Investigator

University of Michigan

RS

Robert Silbergleit

Principal Investigator

University of Michigan

RG

Romer Geocadin

Principal Investigator

Johns Hopkins University

Eligibility Criteria

This trial is for adults who've been in a coma after being resuscitated from a cardiac arrest outside of the hospital. They must be cooled to below 34 degrees Celsius within 4 hours of the event, with plans to maintain life support for at least 96 hours. It's not for those unstable after resuscitation, with pre-existing severe neurological issues or terminal illnesses, planned early life support withdrawal, sepsis-related arrests, or prisoners.

Inclusion Criteria

I am 18 years old or older.
Informed consent from legal authorized representative (LAR) including intent to maintain life support for 96 hours
I joined the study within 6 hours of starting cooling treatment.
See 3 more

Exclusion Criteria

Prisoner
My blood pressure and heart rate are stable.
You have plans to stop life support soon.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive varying durations of induced hypothermia to determine optimal neuroprotection

6 to 72 hours
Continuous monitoring during hospital stay

Rewarming

Controlled rewarming to a temperature of 36.5°C over a period equal to the cooling duration

6 to 72 hours

Follow-up

Participants are monitored for safety and effectiveness after treatment

90 days
Periodic assessments, including neurological and cognitive evaluations

Treatment Details

Interventions

  • Therapeutic Hypothermia
Trial OverviewThe study is testing whether longer periods of induced hypothermia (cooling the body) can improve brain function outcomes in patients who have survived cardiac arrest but are comatose. The goal is to find out how long cooling should last to best protect the brain.
Participant Groups
20Treatment groups
Experimental Treatment
Group I: 72 hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group II: 72 hours - non-shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 72 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group III: 60 hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group IV: 60 hours - non-shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 60 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group V: 6 hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
Group VI: 6 hours - non shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 6 hours of hypothermia with a target of 33 degrees followed by 6 hours of controlled rewarming.
Group VII: 48 hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group VIII: 48 hours - non-shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 48 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group IX: 42 hours - non-shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group X: 42 Hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 42 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group XI: 36 hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group XII: 36 hours - non-shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 36 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group XIII: 30 hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group XIV: 30 hours - non-shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 30 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group XV: 24 hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group XVI: 24 hour - non-shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 24 hours of hypothermia with a target of 33 degrees followed by 24 hours of controlled rewarming.
Group XVII: 18 hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
Group XVIII: 18 hours - non-shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 18 hours of hypothermia with a target of 33 degrees followed by 18 hours of controlled rewarming.
Group XIX: 12 hours - shockableExperimental Treatment1 Intervention
Participants with shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.
Group XX: 12 hours - non-shockableExperimental Treatment1 Intervention
Participants with non-shockable initial rhythm will be assigned to receive 12 hours of hypothermia with a target of 33 degrees followed by 12 hours of controlled rewarming.

Therapeutic Hypothermia is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Therapeutic Hypothermia for:
  • Cardiac arrest in adults and children
  • Birth asphyxia in newborns
🇪🇺
Approved in European Union as Therapeutic Hypothermia for:
  • Cardiac arrest in adults and children
  • Birth asphyxia in newborns
🇨🇦
Approved in Canada as Therapeutic Hypothermia for:
  • Cardiac arrest in adults and children
  • Birth asphyxia in newborns

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Michigan

Lead Sponsor

Trials
1,891
Recruited
6,458,000+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials
1,403
Recruited
655,000+

Medical University of South Carolina

Collaborator

Trials
994
Recruited
7,408,000+

Johns Hopkins University

Collaborator

Trials
2,366
Recruited
15,160,000+

Findings from Research

Therapeutic hypothermia significantly improves survival and neurological outcomes in patients who are comatose after cardiac arrest, making it a crucial part of post-resuscitation care.
Controlled feedback systems for inducing and maintaining hypothermia are more effective than prehospital cooling techniques, as they allow for precise temperature management during treatment.
[Prehospital cardiac arrest. Therapeutic hypothermia in adults].Arntz, HR.[2021]
Mild therapeutic hypothermia, applied immediately after restoring circulation in comatose cardiac arrest survivors, improves neurological outcomes, with 1 additional patient achieving intact neurological function for every 6 treated.
Current research is exploring how hypothermia affects drug metabolism and the best combinations of anesthetics and sedatives, as well as potential new applications for hypothermia in emergency situations like exsanguination cardiac arrest.
Bakken Lecture: the brain, the heart, and therapeutic hypothermia.Kochanek, PM.[2018]
In a study of 12 patients undergoing therapeutic hypothermia after cardiac arrest, temperature measurements from nasopharyngeal and urinary bladder catheters were found to be highly correlated with blood temperature, which is the reference standard.
The findings suggest that both nasopharyngeal and urinary bladder temperature measurements can be reliably used to monitor temperature during therapeutic hypothermia, ensuring accurate temperature control and minimizing cooling-related side effects.
Relationship between blood, nasopharyngeal and urinary bladder temperature during intravascular cooling for therapeutic hypothermia after cardiac arrest.Knapik, P., Rychlik, W., Duda, D., et al.[2012]

References

[Prehospital cardiac arrest. Therapeutic hypothermia in adults]. [2021]
Bakken Lecture: the brain, the heart, and therapeutic hypothermia. [2018]
Relationship between blood, nasopharyngeal and urinary bladder temperature during intravascular cooling for therapeutic hypothermia after cardiac arrest. [2012]
Target temperature within 3 hours: community hospital's experience with therapeutic hypothermia. [2012]
Earlier Hypothermia Attainment is Associated with Improved Outcomes after Cardiac Arrest. [2021]
[Hazards of therapeutic hypothermia]. [2019]
Adverse events and their relation to mortality in out-of-hospital cardiac arrest patients treated with therapeutic hypothermia. [2010]
Induction and maintenance of therapeutic hypothermia after pediatric cardiac arrest: efficacy of a surface cooling protocol. [2021]
Purpura fulminans after therapeutic hypothermia in an asphyxiated neonate with streptococcemia. [2014]
10.United Statespubmed.ncbi.nlm.nih.gov
Practical pharmacologic aspects of therapeutic hypothermia after cardiac arrest. [2022]
Changes in cardiac arrest patients' temperature management after the 2013 "TTM" trial: results from an international survey. [2023]
12.United Statespubmed.ncbi.nlm.nih.gov
Successful Therapeutic Hypothermia in a Propofol-Related Cardiac Arrest Case: A Case Report and Literature Review. [2019]
Therapeutic hypothermia after cardiac arrest: a retrospective comparison of surface and endovascular cooling techniques. [2011]